AAP
AVIR icon

Arax Advisory Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Arax Advisory Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$29 – 3819
2025
Q4 		$29 Sell
8
-191
-96% -$607 ﹤0.01% 3996
2025
Q3 		$577 Buy
+199
New +$680 ﹤0.01% 3352

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arax Advisory Partners's AVIR Position: Q1 2026 in Review

Arax Advisory Partners sold out of Atea Pharmaceuticals (AVIR) in Q1 2026, closing a stake of 8 shares — an estimated $29 sold.

Arax Advisory Partners first reported a position in AVIR in Q3 2025 and held it in 2 quarters. The position peaked at $577 in Q3 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Arax Advisory Partners reported no remaining Atea Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 8 Atea Pharmaceuticals shares in Q1 2026, an estimated $29.
  • Arax Advisory Partners first reported a position in Atea Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Atea Pharmaceuticals position peaked at $577 in Q3 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.